Table 1 Clinical characteristics of 229 patients with IPF at initiations of antifibrotic therapy.

From: Combined assessment of the GAP index and body mass index at antifibrotic therapy initiation for prognosis of idiopathic pulmonary fibrosis

 

IPF combined cohort (n = 229)

Hamamatsu cohort (n = 110)

Seirei cohort (n = 119)

p-value (Hamamatsu cohort vs Seirei cohort)

Age, year

72.0 [67.5–72.0]

72.0 [68.0–75.3]

73.0 [67.0–76.0]

0.8259

Sex, male/female

186 (81.2%)/43 (18.8%)

91 (82.7%)/19 (17.3%)

95 (79.8%)/24 (20.2%)

0.6144

Surgical lung biopsy

50 (21.8%)

35 (31.8%)

15 (12.6%)

0.0007

Diagnosis ~ antifibrotic

13.3 [2.5–45.9]

17.9 [2.2–57.2]

11.5 [2.8–39.1]

0.2081

Follow-up period (anti fibrotic ~)

24.3 [10.8–38.0]

25.8 [12.4–37.9]

21.1 [9.6–38.8]

0.2473

Pirfenidone/nintedanib

140 (61.1%), 89 (38.9%)

76 (69.1%), 34 (30.9%)

64 (53.8%), 55 (46.2%)

0.0211

History of AE

23 (10.0%)

7 (6.4%)

16 (13.4%)

0.0825

Never/former & current smoker

50 (21.8%), 179 (78.2%)

25 (22.7%), 85 (77.3%)

25 (21.0%), 94 (79.0%)

0.8729

Smoking pack-year

30.0 [2.6–48.8]

40.0 [18.0–59.0]

40.0 [18.0–59.0]

0.8122

BMI, kg/m2

23.0 [21.1–25.4]

23.3 [21.4–25.7]

22.8 [20.7–25.3]

0.2837

Pulmonary function test

FVC, %-pred

68.3 [57.0–80.7]

67.2 [55.7–80.4]

69.1 [58.1–81.8]

0.4463

FEV1, %-pred

74.2 [64.1–90.4]

70.7 [59.1–82.9]

79.4 [69.0–93.5]

 < 0.0001

FEV1/FVC, %

85.4 [79.8–91.7]

85.0 [78.5–90.9]

88.0 [80.4–92.9]

0.0759

DLCO, %

59.0 [44.4–71.3] (n = 217)

54.8 [42.4–71.7] (n = 102)

60.8 [45.5–71.2] (n = 115)

0.1676

Laboratory

Hb, g/dl

13.6 [12.5–14.7]

13.5 [12.2–14.6]

13.6 [12.7–14.8]

0.2876

TP, g/dl

7.4 [7.0–7.8]

7.5 [7.1–7.8]

7.4 [6.9–7.9]

0.9728

Alb, g/dl

3.9 [3.6–4.1]

4.0 [3.7–4.2]

3.8 [3.5–4.0]

0.0010

LDH, U/L

230 [203–272]

237 [204–273]

225 [203–270]

0.4627

CRP, mg/dl

0.2 [0.1–0.5]

0.2 [0.1–0.5]

0.2 [0.1–0.5]

0.6172

KL-6, U/ml

1102 [795–1475]

1018 [768–1432]

1169 [855–1673]

0.0507

SP-D ng/ml

247 [157–362]

240 [152–347]

256 [158–395]

0.2178

Treatment

No treatment

145 (63.3%)

81 (73.6%)

64 (53.8%)

0.0025

LTOT

73 (31.9%)

28 (25.5%)

45 (37.8%)

0.0482

Immunosuppressants

39 (17.0%)

11 (10.0%)

28 (23.5%)

0.0080

  1. AE acute exacerbation, BMI body mass index, FVC forced vital capacity, FEV1.0 forced expiratory volume in 1.0 s, DLCO diffuse capacity of the lung for carbon monoxide, KL-6 Krebs von den Lunge-6, SP-D surfactant protein-D, LTOT long-term oxygen therapy.
Back to article page